{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T20:44:39Z","timestamp":1784234679295,"version":"3.55.0"},"reference-count":37,"publisher":"American Society of Hematology","issue":"17","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,9,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Recent compelling evidence showed that innate immune effector cells could recognize allogeneic grafts and prime an adaptive immune response. Signal regulatory protein \u03b1 (SIRP\u03b1) is an immunoglobulin superfamily receptor that is expressed on myeloid cells; the interaction between SIRP\u03b1 and its ubiquitously expressed ligand CD47 elicits an inhibitory signal that suppresses macrophage phagocytic function. Additional studies showed that donor-recipient mismatch in SIRP\u03b1 variants might activate monocytic allorecognition, possibly as the result of non-self SIRP\u03b1-CD47 interaction. However, the frequency of SIRP\u03b1 variation and its role in hematopoietic stem cell transplantation (HSCT) remains unexplored. We studied 350 patients with acute myeloid leukemia\/myelodysplastic syndrome who underwent HLA-matched related HSCT and found that SIRP\u03b1 allelic mismatches were present in 39% of transplantation pairs. SIRP\u03b1 variant mismatch was associated with a significantly higher rate of chronic graft-versus-host disease (GVHD; hazard ratio [HR], 1.5; P = .03), especially de novo chronic GVHD (HR, 2.0; P = .01), after adjusting for other predictors. Those with mismatched SIRP\u03b1 had a lower relapse rate (HR, 0.6; P = .05) and significantly longer relapse-free survival (RFS; HR, 0.6; P = .04). Notably, the effect of SIRP\u03b1 variant mismatch on relapse protection was most pronounced early after HSCT and in patients who were not in remission at HSCT (cumulative incidence, 73% vs 54%; HR, 0.5; P = .01). These findings show that SIRP\u03b1 variant mismatch is associated with HSCT outcomes, possibly owing to innate allorecognition. SIRP\u03b1 variant matching could provide valuable information for donor selection and risk stratification in HSCT.<\/jats:p>","DOI":"10.1182\/bloodadvances.2021004307","type":"journal-article","created":{"date-parts":[[2021,9,8]],"date-time":"2021-09-08T18:59:46Z","timestamp":1631127586000},"page":"3407-3417","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":8,"title":["Mismatch in SIRP\u03b1, a regulatory protein in innate immunity, is associated with chronic GVHD in hematopoietic stem cell transplantation"],"prefix":"10.1182","volume":"5","author":[{"given":"Rima M.","family":"Saliba","sequence":"first","affiliation":[{"name":"Department of Stem Cell Transplantation and Cellular Therapy,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uri","family":"Greenbaum","sequence":"additional","affiliation":[{"name":"Department of Stem Cell Transplantation and Cellular Therapy,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Stem Cell Transplantation and Cellular Therapy,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samer A.","family":"Srour","sequence":"additional","affiliation":[{"name":"Department of Stem Cell Transplantation and Cellular Therapy,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yudith","family":"Carmazzi","sequence":"additional","affiliation":[{"name":"Division of Pathology\/Laboratory Medicine, Department of Laboratory Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Biostatistics;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betul","family":"Oran","sequence":"additional","affiliation":[{"name":"Department of Stem Cell Transplantation and Cellular Therapy,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Moller","sequence":"additional","affiliation":[{"name":"Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7314-0790","authenticated-orcid":false,"given":"Janet","family":"Wood","sequence":"additional","affiliation":[{"name":"Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8597-3271","authenticated-orcid":false,"given":"Stefan O.","family":"Ciurea","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine, Chao Family Comprehensive Cancer Center, University of California, Irvine, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piyanuch","family":"Kongtim","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine, Chao Family Comprehensive Cancer Center, University of California, Irvine, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Rondon","sequence":"additional","affiliation":[{"name":"Department of Stem Cell Transplantation and Cellular Therapy,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Partlow","sequence":"additional","affiliation":[{"name":"Division of Pathology\/Laboratory Medicine, Department of Laboratory Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8303-406X","authenticated-orcid":false,"given":"Dan","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Stem Cell Transplantation and Cellular Therapy,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katayoun","family":"Rezvani","sequence":"additional","affiliation":[{"name":"Department of Stem Cell Transplantation and Cellular Therapy,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth J.","family":"Shpall","sequence":"additional","affiliation":[{"name":"Department of Stem Cell Transplantation and Cellular Therapy,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Cao","sequence":"additional","affiliation":[{"name":"Division of Pathology\/Laboratory Medicine, Department of Laboratory Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4314-5037","authenticated-orcid":false,"given":"Richard E.","family":"Champlin","sequence":"additional","affiliation":[{"name":"Department of Stem Cell Transplantation and Cellular Therapy,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0112-5118","authenticated-orcid":false,"given":"Jun","family":"Zou","sequence":"additional","affiliation":[{"name":"Division of Pathology\/Laboratory Medicine, Department of Laboratory Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2021,9,8]]},"reference":[{"issue":"8","key":"2021090815382034100_B1","doi-asserted-by":"crossref","first-page":"a014993","DOI":"10.1101\/cshperspect.a014993","article-title":"Origin and biology of the allogeneic response","volume":"3","author":"Lakkis","year":"2013","journal-title":"Cold Spring Harb Perspect Med."},{"issue":"6","key":"2021090815382034100_B2","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1182\/blood-2014-06-582460","article-title":"Haploidentical transplantation: the search for the best donor","volume":"124","author":"Handgretinger","year":"2014","journal-title":"Blood."},{"issue":"4","key":"2021090815382034100_B3","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/nri2215","article-title":"How dying cells alert the immune system to danger","volume":"8","author":"Kono","year":"2008","journal-title":"Nat Rev Immunol."},{"issue":"8","key":"2021090815382034100_B4","doi-asserted-by":"crossref","first-page":"3579","DOI":"10.1172\/JCI74370","article-title":"Non-self recognition by monocytes initiates allograft rejection","volume":"124","author":"Oberbarnscheidt","year":"2014","journal-title":"J Clin Invest."},{"issue":"12","key":"2021090815382034100_B5","doi-asserted-by":"crossref","first-page":"7810","DOI":"10.4049\/jimmunol.0902194","article-title":"An innate response to allogeneic nonself mediated by monocytes","volume":"183","author":"Zecher","year":"2009","journal-title":"J Immunol."},{"issue":"3","key":"2021090815382034100_B6","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.it.2017.12.005","article-title":"SIRP\u03b1-CD47 immune checkpoint blockade in anticancer therapy","volume":"39","author":"Veillette","year":"2018","journal-title":"Trends Immunol."},{"issue":"12","key":"2021090815382034100_B7","doi-asserted-by":"crossref","first-page":"3263","DOI":"10.1111\/ajt.15497","article-title":"SIRP\u03b1\/CD47 axis controls the maintenance of transplant tolerance sustained by myeloid-derived suppressor cells","volume":"19","author":"Pengam","year":"2019","journal-title":"Am J Transplant."},{"issue":"2","key":"2021090815382034100_B8","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.cell.2009.05.045","article-title":"CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells","volume":"138","author":"Majeti","year":"2009","journal-title":"Cell."},{"issue":"25","key":"2021090815382034100_B9","doi-asserted-by":"crossref","first-page":"4013","DOI":"10.1182\/blood-2013-06-506949","article-title":"BLT-humanized C57BL\/6 Rag2-\/-\u03b3c-\/-CD47-\/- mice are resistant to GVHD and develop B- and T-cell immunity to HIV infection","volume":"122","author":"Lavender","year":"2013","journal-title":"Blood."},{"issue":"9","key":"2021090815382034100_B10","doi-asserted-by":"crossref","first-page":"4574","DOI":"10.1172\/JCI133909","article-title":"Donor monocyte-derived macrophages promote human acute graft-versus-host disease","volume":"130","author":"Jardine","year":"2020","journal-title":"J Clin Invest."},{"issue":"12","key":"2021090815382034100_B11","doi-asserted-by":"crossref","first-page":"eaam6202","DOI":"10.1126\/sciimmunol.aam6202","article-title":"Donor SIRP\u03b1 polymorphism modulates the innate immune response to allogeneic grafts","volume":"2","author":"Dai","year":"2017","journal-title":"Sci Immunol."},{"issue":"6","key":"2021090815382034100_B12","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/j.kint.2017.10.006","article-title":"Donor SIRP-\u03b1 polymorphisms: widening the innate-to-adaptive continuum in allograft rejection","volume":"92","author":"Menon","year":"2017","journal-title":"Kidney Int."},{"issue":"12","key":"2021090815382034100_B13","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1038\/ni1527","article-title":"Polymorphism in Sirpa modulates engraftment of human hematopoietic stem cells","volume":"8","author":"Takenaka","year":"2007","journal-title":"Nat Immunol."},{"issue":"6","key":"2021090815382034100_B14","first-page":"825","article-title":"1994 Consensus Conference on Acute GVHD Grading","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant."},{"issue":"2","key":"2021090815382034100_B15","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1182\/blood.V57.2.267.267","article-title":"Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression","volume":"57","author":"Sullivan","year":"1981","journal-title":"Blood."},{"key":"2021090815382034100_B16","author":"Center for Internationl Blood and Marrow Transplant"},{"issue":"3","key":"2021090815382034100_B17","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1182\/blood-2009-07-235358","article-title":"Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet","volume":"115","author":"D\u00f6hner","year":"2010","journal-title":"Blood."},{"issue":"6","key":"2021090815382034100_B18","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","article-title":"International scoring system for evaluating prognosis in myelodysplastic syndromes","volume":"89","author":"Greenberg","year":"1997","journal-title":"Blood."},{"issue":"6122","key":"2021090815382034100_B19","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1126\/science.1229568","article-title":"Minimal \u201cself\u201d peptides that inhibit phagocytic clearance and enhance delivery of nanoparticles","volume":"339","author":"Rodriguez","year":"2013","journal-title":"Science."},{"issue":"24","key":"2021090815382034100_B20","doi-asserted-by":"crossref","first-page":"6426","DOI":"10.1182\/blood-2011-06-358747","article-title":"Mechanisms of antigen presentation to T cells in murine graft-versus-host disease: cross-presentation and the appearance of cross-presentation","volume":"118","author":"Wang","year":"2011","journal-title":"Blood."},{"key":"2021090815382034100_B21","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/j.bbmt.2012.11.005","article-title":"Biology of graft-versus-host responses: recent insights","volume":"19","author":"MacDonald","year":"2013","journal-title":"Biol Blood Marrow Transplant."},{"issue":"9","key":"2021090815382034100_B22","doi-asserted-by":"crossref","first-page":"4532","DOI":"10.1172\/JCI140064","article-title":"Alternative mechanisms that mediate graft-versus-host disease in allogeneic hematopoietic cell transplants","volume":"130","author":"Young","year":"2020","journal-title":"J Clin Invest."},{"issue":"9","key":"2021090815382034100_B23","doi-asserted-by":"crossref","first-page":"4624","DOI":"10.1172\/JCI129965","article-title":"Peripheral host T cells survive hematopoietic stem cell transplantation and promote graft-versus-host disease","volume":"130","author":"Divito","year":"2020","journal-title":"J Clin Invest."},{"issue":"2","key":"2021090815382034100_B24","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1182\/blood.V100.2.406","article-title":"Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse","volume":"100","author":"Lee","year":"2002","journal-title":"Blood."},{"issue":"6","key":"2021090815382034100_B25","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1182\/blood.V73.6.1720.1720","article-title":"Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia","volume":"73","author":"Sullivan","year":"1989","journal-title":"Blood."},{"issue":"10","key":"2021090815382034100_B26","first-page":"1380","article-title":"Anti-leukemic effect of graft-versus-host disease on bone marrow and extramedullary relapses in acute leukemia","volume":"90","author":"Lee","year":"2005","journal-title":"Haematologica."},{"issue":"2","key":"2021090815382034100_B27","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/bjh.13959","article-title":"Advances in understanding the pathogenesis of graft-versus-host disease","volume":"173","author":"Magenau","year":"2016","journal-title":"Br J Haematol."},{"issue":"1","key":"2021090815382034100_B28","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1182\/blood-2016-06-686618","article-title":"Chronic graft-versus-host disease: biological insights from preclinical and clinical studies","volume":"129","author":"MacDonald","year":"2017","journal-title":"Blood."},{"issue":"9","key":"2021090815382034100_B29","doi-asserted-by":"crossref","first-page":"4344","DOI":"10.4049\/jimmunol.1400181","article-title":"IL-17A influences essential functions of the monocyte\/macrophage lineage and is involved in advanced murine and human atherosclerosis","volume":"193","author":"Erbel","year":"2014","journal-title":"J Immunol."},{"issue":"4","key":"2021090815382034100_B30","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1111\/odi.12936","article-title":"Chronic graft-versus-host disease: Current management paradigm and future perspectives","volume":"25","author":"Mawardi","year":"2019","journal-title":"Oral Dis."},{"issue":"9","key":"2021090815382034100_B31","doi-asserted-by":"crossref","first-page":"3490","DOI":"10.4049\/jimmunol.1601054","article-title":"Upregulation of IFN-inducible and damage-response pathways in chronic graft-versus-host disease","volume":"197","author":"Hakim","year":"2016","journal-title":"J Immunol."},{"issue":"10","key":"2021090815382034100_B32","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.12998\/wjcc.v8.i10.1793","article-title":"Macrophage regulation of graft-vs-host disease","volume":"8","author":"Hong","year":"2020","journal-title":"World J Clin Cases."},{"issue":"8","key":"2021090815382034100_B33","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/j.bbmt.2017.04.019","article-title":"Association of plasma CD163 concentration with de novo-onset chronic graft-versus-host disease","volume":"23","author":"Inamoto","year":"2017","journal-title":"Biol Blood Marrow Transplant."},{"issue":"5","key":"2021090815382034100_B34","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.bbmt.2015.01.003","article-title":"National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: III. The 2014 Biomarker Working Group Report","volume":"21","author":"Paczesny","year":"2015","journal-title":"Biol Blood Marrow Transplant."},{"issue":"12","key":"2021090815382034100_B35","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","article-title":"National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report","volume":"11","author":"Filipovich","year":"2005","journal-title":"Biol Blood Marrow Transplant."},{"issue":"1","key":"2021090815382034100_B36","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1186\/s40425-019-0772-0","article-title":"Functional characterization of the selective pan-allele anti-SIRP\u03b1 antibody ADU-1805 that blocks the SIRP\u03b1-CD47 innate immune checkpoint","volume":"7","author":"Voets","year":"2019","journal-title":"J Immunother Cancer."},{"issue":"14","key":"2021090815382034100_B37","doi-asserted-by":"crossref","first-page":"10024","DOI":"10.1074\/jbc.M114.550558","article-title":"Polymorphisms in the human inhibitory signal-regulatory protein \u03b1 do not affect binding to its ligand CD47","volume":"289","author":"Hatherley","year":"2014","journal-title":"J Biol Chem."}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/17\/3407\/1821157\/advancesadv2021004307.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/17\/3407\/1821157\/advancesadv2021004307.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,8]],"date-time":"2021-09-08T19:00:12Z","timestamp":1631127612000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/5\/17\/3407\/476734\/Mismatch-in-SIRP-a-regulatory-protein-in-innate"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,8]]},"references-count":37,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2021,9,14]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2021004307","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,8]]}}}